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Abstract
Respiratory Syncytial Virus (RSV) is a major cause of viral brochiolitis in infants and young children and is also a significant
problem in elderly and immuno-compromised adults. To date there is no efficacious and safe RSV vaccine, partially because
of the outcome of a clinical trial in the 1960s with a formalin-inactivated RSV vaccine (FI-RSV). This vaccine caused enhanced
respiratory disease upon exposure to the live virus, leading to increased morbidity and the death of two children.
Subsequent analyses of this incident showed that FI-RSV induces a Th2-skewed immune response together with poorly
neutralizing antibodies. As a new approach, we used reconstituted RSV viral envelopes, i.e. virosomes, with incorporated
monophosphoryl lipid A (MPLA) adjuvant to enhance immunogenicity and to skew the immune response towards a Th1
phenotype. Incorporation of MPLA stimulated the overall immunogenicity of the virosomes compared to non-adjuvanted
virosomes in mice. Intramuscular administration of the vaccine led to the induction of RSV-specific IgG2a levels similar to
those induced by inoculation of the animals with live RSV. These antibodies were able to neutralize RSV in vitro.
Furthermore, MPLA-adjuvanted RSV virosomes induced high amounts of IFNc and low amounts of IL5 in both spleens and
lungs of immunized and subsequently challenged animals, compared to levels of these cytokines in animals vaccinated with
FI-RSV, indicating a Th1-skewed response. Mice vaccinated with RSV-MPLA virosomes were protected from live RSV
challenge, clearing the inoculated virus without showing signs of lung pathology. Taken together, these data demonstrate
that RSV-MPLA virosomes represent a safe and efficacious vaccine candidate which warrants further evaluation.
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Introduction
Respiratory Syncytial Virus (RSV) is a major cause of viral
brochiolitis in infants and young children and is also a significant
problem in elderly and immuno-compromised adults. According
to the WHO, annually 64 million people are infected with RSV,
and 160,000 people die from the infection around the world [1]. It
is estimated that, each year, RSV leads to 3.4 million hospitaliza-
tions of children [2]. By the age of two, nearly all children have
been infected with RSV. However, natural infection does not
evoke long-lasting immunity, which causes people to undergo
multiple RSV infections throughout their lives. In healthy adults,
RSV infection will manifest itself like a common cold, which is
generally cleared within two weeks. When, at old age, the immune
system weakens, RSV infections become more severe, leading to,
for example, approximately 10,000 deaths in nursing homes in the
US each year [3,4]. Current treatment of RSV infection in high-
risk infants consists of prophylactic administration of the mono-
clonal antibody Palivizumab [5]. However, the high costs of
monoclonal antibody therapy and the limited duration of efficacy
of this treatment warrant the development of an RSV vaccine
[6,7] In elderly, treatment is mainly supportive and consists of
administration of fluids, oxygen and antipyretics [8]. Aerosolized
Ribavirin is registered for use in some infant groups however, no
significant effect has been reported in the elderly [8].
Even though the need for an RSV vaccine has been recognized
for over 60 years, there is currently no licensed RSV vaccine
available. This is, in part, due to the disastrous outcome of
a clinical trial in the 1960s, which evaluated a formalin-
inactivated, alum-adjuvanted, RSV (FI-RSV) vaccine candidate
[9–12]. In this trial, children who received the vaccine developed
RSV-specific antibodies, but these proved to be poorly virus-
neutralizing [13,14]. Instead of preventing infection, vaccination
resulted in enhanced respiratory disease (ERD) upon infection
with the live virus, leading to a 16-fold increase in hospitalization
and even to the death of two children in the vaccinated group [15].
After this trial, many studies have been performed to elucidate the
mechanisms causing ERD upon vaccination with FI-RSV and
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36812
subsequent exposure to live virus. Studies in mice, for example,
showed that a Th2-like immune response accompanied by influx
of eosinophils into the lungs plays a major role in ERD [16].
Another study in mice has shown that, although FI-RSV does
elicit RSV-specific antibodies, these have a limited affinity for
neutralizing epitopes on the RSV fusion protein due to lack of
affinity maturation [17]. Therefore, a future RSV vaccine should
induce a Th1-skewed response together with high levels of strongly
neutralizing antibodies.
A promising approach towards the development of vaccines that
both skew the immune response to a Th1-type reaction and induce
high-affinity antibodies is to include Toll-Like Receptor (TLR)
ligands in the vaccine [18]. TLRs recognize Pathogen-Associated
Molecular Patterns (PAMPs) from bacteria and viruses and sub-
sequently signal through adaptor molecules such as MyD88 and
TRIF to induce the production of inflammatory cytokines and type-I
interferons [19]. Activation of TLR4, for example, leads to
production of high amounts of IL12 and IFNc resulting in a Th1-
skewed immune response [20]. Importantly, a recent study showed
that a UV-inactivated RSV virus, which by itself induces poorly
neutralizing antibodies, will give rise to high-affinity and strongly
neutralizing antibodies when supplemented with TLR ligands [17].
Using a similar approach, we recently showed that the incorporation
of the TLR2 ligand P3CSK4 in an experimental virosomal RSV
vaccine promotes the capacity of the vaccine to induce Th1-type
cellular responses together with the induction of protective
antibodies in mice and cotton rats [21]. Thus, the combination of
an RSV vaccine, such as RSV virosomes, with a TLR ligand
improves both the immunogenicity and the safety of the vaccine.
Another promising TLR ligand candidate to be used as an
adjuvant in an RSV vaccine is the TLR4 ligand monophosphoryl
lipid A (MPLA) [22]. MPLA is a detoxified derivative of bacterial
lipopolysaccharide (LPS) [23]. Like LPS, MPLA also signals
through TLR4. However, where TLR4 activation by LPS induces
signaling through adaptor molecule MyD88, activation by MPLA
leads to TRIF-mediated signaling, resulting in enhanced type I
IFN production and reduced production of inflammatory
cytokines compared to MyD88-mediated signaling [17,24,25].
MPLA stimulates the production of IFNc by antigen-specific
CD4+ T-cells indicating a Th1-skewed response [22,26]. While
the TLR2 ligand P3CSK4, which we used in our previous study
[21], has been associated with a balanced Th1/Th2-type immune
response, MPLA is thus known to induce a significantly Th1-
skewed immune response [27]. Furthermore, an MPLA derivative
with similar immune-potentiating properties as native MPLA has
been evaluated in extensive clinical trials and has shown good
efficacy combined with an acceptable safety profile for use in
humans when co-administered with a variety of antigens [28]. For
these reasons, MPLA is the only TLR ligand which is currently
being used as an adjuvant in a number of licensed vaccines
[29,30]. Importantly, the addition of MPLA to FI-RSV suppressed
the expression of RSV ERD associated cytokines in the lungs of
cotton rats [31]. Furthermore, it has been shown that addition of
MPLA to FI-RSV promotes the immunogenicity of the vaccine
and ameliorates lung pathology after challenge [32]. Thus, the
favorable Th1-inducing properties of MPLA, compared to
P3CSK4, combined with the available data on the inhibitory
effects of this TLR ligand on the development of RSV ERD and
its acceptable safety profile in humans, led us to explore MPLA as
a possible adjuvant in our RSV virosomal vaccine.
We exploited the lipophilic properties of MPLA to incorporate
it in the virosomal membrane during the reconstitution process.
These virosomes were analyzed for their immunostimulating
properties and immunogenicity both in vitro and in vivo and for their
capacity to induce protection against infection with live RSV. Our
data show that incorporation of MPLA in RSV virosomes
increases their immunostimulatory capacity in vitro, as evidenced
by increased human TLR4-mediated NF-kB activation and
upregulation of costimulatory molecules in mouse dendritic cells.
In vivo, incorporation of MPLA in RSV virosomes stimulated
RSV-specific IgG antibody levels, with increased IgG2a antibody
production and increased levels of virus neutralizing antibodies
compared to non-adjuvanted RSV virosomes. Also, RSV-MPLA
virosomes primed for Th1-type responses as evidenced by high
IFNc levels and low IL5 levels, not only in ex vivo cultures of
splenocytes from immunized mice stimulated with RSV antigen,
but also in the lungs of immunized mice upon challenge with live
RSV. Finally, mice vaccinated with RSV-MPLA virosomes were
protected from challenge with live RSV without symptoms of
ERD, as demonstrated by the absence of lung pathology and a lack
of eosinophil infiltration into the lungs.
Materials and Methods
Ethical Statement
Animal experiments were evaluated and approved by the
Committee for Animal Experimentation (DEC) of the University
Medical Center Groningen, according to the guidelines provided by
the Dutch Animal Protection Act (permit number DEC 5239A).
Immunizations and challenges were conducted under isofluorane
anesthesia, and every effort was made to minimize suffering.
Virus and Cell Culture
RSV strain A2 (ATCC VR1540) was kindly donated by
Mymetics BV (Leiden, The Netherlands). The virus was grown in
roller bottles on HEp-2 cells (ATCC, CL-23, Wesel, Germany) in
HEp-2 medium: DMEM (Invitrogen, Breda, The Netherlands)
supplemented with Pen/Strep, L-Glutamine, Sodium bicarbonate,
HEPES, Sodium Pyruvate, 1X non-essential Amino Acids (all
from Invitrogen) and 10% FBS (Lonza-Biowhittaker, Basel,
Switzerland) unless stated otherwise. At 80% CPE (5 days post-
infection) the medium was cleared by low-speed centrifugation.
Aliquots of the supernatant were snap-frozen in liquid nitrogen, as
a source of live virus for immunization and challenge. The
remainder of the virus was pelleted by ultracentrifugation and
subsequently purified on a sucrose gradient. Purified virus was
snap-frozen in liquid nitrogen and stored at 280uC in 20%
sucrose in HNE buffer (5 mM Hepes, 145 mM NaCl, 1 mM
EDTA, pH 7.4).
Mouse dendritic cells (DCs) were derived from bone-marrow
cultures, as described before [33]. Briefly, both tibia and femurs
were flushed with Iscove’s modified DMEM (IMDM; Invitrogen,)
supplemented with 10% FBS, pen/strep, 0.1% b-mercaptoethanol
(Invitrogen). Red blood cells were lysed by incubating the cells
with ACK buffer (0.83% NH4Cl, 10 mM KHCO3, 0.1 mM
EDTA, pH 7.2) for 5 min on ice. The cells were washed with
IMDM medium and incubated in IMDM medium supplemented
with 200 ng/ml Fms-like tyrosine kinase 3 ligand (Flt3L)(R&D
systems, Abingdon, UK). Medium was replaced after 4 days and
dendritic cells were harvested 8 days after initiation of the culture.
HEK-Blue TLR4 and HEK-Blue Null2 cells were purchased
from Invivogen (Toulouse, France) and maintained according to
the manufacturer’s protocol.
Vaccine Production
RSV virosomes were generated as described previously [21].
Briefly, purified RSV was pelleted by ultracentrifugation and
dissolved in 100 mM 1,2 dihexanoyl-sn-glycero-3-phosphocholine
MPLA Adjuvanted RSV Virosomes in Mice
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(DCPC) in HNE buffer. The nucleocapsid was removed by
ultracentrifugation. Subsequently, a 2:1 molar mixture of egg
phosphatidylcholine (PC) and egg phosphatidylethanolamine (PE)
(Avanti Polar Lipids, Alabaster, AL, USA) in 2:1 chloroform/
methanol at 850 nmol/mg protein was evaporated to a dry film in
a glass tube. The supernatant containing the membrane lipids and
proteins was added to the lipid mixture. For incorporation of
MPLA, monophosphoryl lipid A from Salmonella minnesota Re 595
(Invivogen) was first dissolved in 100 mM DCPC in HNE buffer
and then added to the protein/lipid mixture at 1 mg MPLA/mg
virosomal protein. For the MPLA concentration experiment,
MPLA was added in lower ratios i.e. 1:0.2, 1:0.04, 1:0.008 (mg
virosomal protein to mg MPLA). The mixture was incubated for
15 min at 4uC, filtered through a 0.22 mm filter and dialyzed in
a sterile Slide-A-lyzer (10 kD cut-off; Thermo Scientific, Geel,
Belgium) against 462 liters of HNE pH 7.4 for 48 hours. After
dialysis, virosomes were kept at 4uC.
FI-RSV vaccine was produced according to the original
protocol, which was used for the 1960’s FI-RSV preparation as
reported in [34]. FI-RSV was diluted in HNE buffer to contain
5 mg of RSV protein in 25 ml of vaccine.
In vitro Analyses
The virosomes were analyzed by equilibrium density gradient
centrifugation on 10–60% sucrose gradients in HNE. Gradients
were spun for 60 hr in an SW 55 Ti rotor at 50000 rpm and
samples from the gradient were analyzed for protein, phospholipid
phosphate and density (by refractometry). Each fraction was
dialyzed against HNE in a Slide-A-Lyzer MINI Dialysis Device
(Thermo Scientific, Geel, Belgium) overnight to remove the
sucrose which is toxic for HEK-Blue cells at high concentrations.
The samples were corrected for increases in volume due to the
dialysis and 20 ml volumes of the samples were used to stimulate
HEK-Blue TLR4 cells (105 cells/well) and HEK blue Null2 cells
(56104 cells per well) overnight at 37uC in a 96 well plate in
triplicate. To quantify alkaline phosphatase production, 20 ml of
HEK-Blue cell supernatant was added to 180 ml Quanti-Blue
(Invivogen, Toulouse, France) and incubated for 30 minutes at
37uC. Absorbance was measured at 630 nm and plotted relative to
the activation induced by 100 ng/ml of TNFa.
Upregulation of surface markers was assessed after incubating
DCs with different virosome preparations. DCs were incubated at
16106 cells/ml at 37uC in IMDM medium. The incubation was
stopped after 24 hr by washing the cells twice in medium.
Expression of surface markers was determined by staining with
anti-mouse CD80-PE (12-0801-82, eBioscience, Vienna, Austria)
anti-mouse CD86- PE (12-0862-82, eBioscience) and anti-mouse
CD40-FITC (11-0402-82, eBioscience) using standard staining
protocols, followed by flow-cytometric analysis on a FACSCalibur
flow cytometer (BD Bio- sciences, Erembodegem, Belgium).
Animal Experiments
Female specified-pathogen-free BALB/c OlaHsd mice (6–8
weeks old) (Harlan, Zeist, The Netherlands) were used for all
immunization experiments. For immunization and challenge, mice
were anesthetized using 3–4.5% isoflurane in O2. Mice received
RSV virosomes, RSV-MPLA virosomes or FI-RSV intramuscu-
larly in 25 ml HNE. Each preparation contained 5 mg of protein.
Control mice received 50 ml (1*106 TCID50) of live RSV,
intranasally or 25 ml of HNE intramuscularly. Vaccinations were
given on day 0 and day 14. On day 28 mice were challenged with
106 TCID50 (titrated as described below) of live RSV intranasally.
On time points of vaccination and challenge, blood was drawn by
retro-orbital puncture. Four days after challenge, mice were
sacrificed and blood was drawn by heart puncture. Spleens were
harvested for analysis of RSV-specific T cell cytokine responses
and lungs for analysis of pathology, determination of lung
cytokines and viral titers, respectively.
Virus Titration
Virus titers were determined by titration of the tissue-culture
infectious dose (TCID50). For challenge virus, initial dilutions of
1:5000 were made in HEp-2 medium without FBS. Serial twofold
dilutions of these samples were made in 96-well plates in
quadruplicate. 20,000 HEp-2 cells were added to the virus
dilutions and incubated for 5 days at 37uC in 5% CO2. The cells
were then fixed with 1% paraformaldehyde in PBS for 45 min,
blocked with 2% milk powder (Protifar plus, Nutricia, Zoetermeer,
The Netherlands) in PBS for 1 hr and stained with 50 ml 1:400
FITC-labeled goat anti-RSV antibody (Meridian life science Inc,
Saco, ME, USA) at 37uC overnight. The next day, plates were
washed with PBS and analyzed under a fluorescence microscope.
Wells were considered positive for infection if one or more
fluorescent syncytium was present. Titers were calculated using the
Reed & Muench method.
To determine virus titers in the lungs of challenged mice, the
lungs were removed aseptically after euthanasia of the mice. Lungs
were then homogenized in 1 ml of 2% FBS containing HEp-2
medium using an automated Potter homogenizer Polytron-
AggregateH (Thomas Scientific, Swedesboro, NJ, USA). Next,
homogenates were centrifuged at 1400 rpm for 10 min at 4uC,
and supernatants, diluted to a 1:5 starting dilution, were used to
determine viral titers using the TCID50 method as described
above.
In vitro Neutralization Assay
Volumes of 100 ml of serum were heat-inactivated for 30 min at
56uC and subsequently diluted with 150 ml serum-free HEp2
medium. Wells of 96-well plates were filled with 50 ml of serum
free HEp2 medium. Fifty ml of diluted serum was applied to the
first row of wells in quadruplicate and serial two-fold dilutions
were made. Subsequently, 70 TCID50 of live RSV was added in
50 ml of serum free HEp2 medium and incubated at 37uC for
2 hr. After incubation, 20,000 HEp2 cells were added per well in
100 ml of HEp2 medium with 4% FBS. After 5 days of incubation,
the cells were washed, fixed and stained as described above for the
virus titration. Neutralization titer was calculated with the Reed &
Muench method and is indicated as the reciprocal of the dilution
that neutralizes infection in 50% of the wells.
Immunological Assays
RSV-specific antibody titers were determined as described
before [21]. Briefly, 96-well plates were coated with betapro-
piolactone-inactivated RSV and then blocked with 2.5% milk
powder in coating buffer. Plates were then incubated for 90 min
with two-fold serial dilutions of serum or broncho-alveolar
lavages (BAL; see below), starting at 1:200 for serum or 1:1 for
BAL. After washing, plates were incubated with a 1:5000
dilution of horseradish-peroxidase-coupled goat anti-mouse IgG,
IgG1, IgG2a, IgA, or rat anti-mouse IgE (Southern Biotech
1030-05, 1070-05, 1080-05, 1040-05, 1130-05) for 1 hr, washed
again and subsequently stained with o-Phenylenediamine (OPD;
Sigma-Aldrich, St Louis, MO, USA). After 30 min the staining
was stopped by addition of 2 M H2SO4 and absorption was
measured at 492 nm. For levels of total IgG, geometric mean
titers (GMT) were determined. For quantification of IgG1 and
IgG2a levels, a calibration curve was used. For this, ELISA
plates were coated with goat anti-mouse-IgG (heavy and light
MPLA Adjuvanted RSV Virosomes in Mice
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chain, human absorbed; Southern Biotech, 1031-01) at 100 ng/
well in coating buffer overnight at 37uC. After blocking with
2.5% milk powder, known concentrations of a mouse IgG1
isotype control (Southern Biotech, 1070-01) and mouse IgG2a
isotype control (Southern Biotech, 0103-01) were prepared, and
applied to the plates. After a 90-min incubation at 37uC, plates
were washed and stained as described above.
For analysis of levels of IL5 and IFNc in splenocyte cultures and
lung homogenates (see below), mouse IFN-c and mouse IL5 high
sensitivity ELISA kits (eBioscience) were used according to the
manufacturer’s instruction.
For the analysis of IFN-c and IL5 secretion in the RSV-
specific recall responses of splenocytes, spleens were removed
four days after challenge and transferred to a 15 ml tube
containing IMDM/10% FCS. The spleens were passed through
a 70-mm cell strainer (BD Biosciences, Heidelberg, Germany)
using sterile 3-mL syringe plungers. Erythrocytes were then lysed
by incubating with ACK buffer for 5 min on ice. The cells were
washed with medium, counted and seeded at 26106 cells/ml and
stimulated with BPL-RSV (10 mg/mL) in IMDM/10% FCS in
triplicates and incubated at 37uC in a 5% CO2 atmosphere for
72 hr. Supernatants were harvested and stored at 220uC until
further analysis.
For analysis of IL5 and IFNc levels in RSV-infected lungs, lungs
were removed from challenged mice and homogenized using the
method as described for virus titration (see above). IL5 and IFNc
levels were then determined in supernatants of centrifuged lung
homogenates.
Lung Histopathology
The harvested lung lobes were inflated with 4% formalin in PBS
and subsequently embedded in paraffin. Four mm slices were then
prepared, and stained with standard hematoxylin and eosin. After
staining, lung inflammatory parameters (peribronchiolitis, periva-
culitis and alveolitis) were assessed by light microscopic analysis of
slides.
Broncho-alveolar Lavage Cytospins
BAL were taken by rinsing the lungs of the mice with 1 ml of
PBS supplemented with protease inhibitors using a winged
shielded i.v. catheter (1.3630 mm, BD Utah) inserted, through
an incision, in the trachea of euthanized mice. Cells in the BAL
were pelleted by low-speed centrifugation and resuspended in
500 ml PBS. In some cases, the remaining BAL supernatants were
used for IgA antibody assessment in ELISA. Subsequently, cells
were spotted (300 rpm for 5 min) onto glass slides, air dried, and
fixed in 80% methanol/20% PBS (V/V) for 10 min at 220uC.
After air-drying, slides were stained for 20 min in May-Grunwald-
Giemsa stain (Merck, Darmstadt, Germany), diluted 1:1 in
Sørensen’s phosphate buffer (0.2 M; pH 6.6). Then, slides were
rinsed in Sørensen’s phosphate buffer, and incubated for 15 min
in Giemsa stain (Merck, Darmstadt, Germany) diluted 1:8 in
Sørensen’s phosphate buffer. After washing with tap water, slides
were air-dried and spots were sealed using cover slides and
Kaiser’s glycerol (Merck, Darmstadt, Germany). The presence of
eosinophils in cytospot BAL cells was analyzed by light micros-
copy.
Statistical Analysis
All statistical analyses were performed with Graphad Prism 5.00
for Mac OSX, (GraphPad Software, San Diego California USA,
www.graphpad.com. Statistical significance was assessed using
a Mann-Whitney U test. A P value of 0.05 or lower was considered
to represent a significant difference.
Figure 1. In vitro analysis of RSV and RSV-MPLA virosomes. (A,B) RSV virosomes and RSV-MPLA virosomes were spun on an equilibrium
density sucrose gradient. Subsequently, density, protein concentration, and phosphate concentrations of each fraction was determined. (C,D)
Fractions from A and B were analyzed for their TLR4-signaling ability using Hek-Blue TLR4 cells. To assess non-TLR specific activation of cells, control
cells (Null2 cells) were incubated with the same virosome fractions. As a control for activation both Hek blue TLR4 and Hek blue null2 cells were
stimulated with 100 ng/ml TNF-a. Bars represent TLR activation relative to that of the TNF-a control (E) Upregulation of DCs costimulatory molecules
CD40, CD86, CD80. Unfractionated virosome preparations were used to stimulate ex vivo cultured mouse DCs overnight. Cells were stained for
expression of costimulatory molecules using specific monoclonal antibodies and analyzed by FACS. Bars represent the percentage of positive cells.
The data shown are a representative of three individual experiments.
doi:10.1371/journal.pone.0036812.g001
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Results
Characterization of RSV-MPLA Virosomes
The formation of virosomes was analyzed by equilibrium
density-gradient centrifugation. Protein and phosphate were found
to co-migrate for RSV virosome preparations with and without
MPLA, indicating successful reconstitution of the viral envelopes
(Figure 1A, 1B). For RSV-MPLA virosomes, the apparent absence
of phosphate outside the virosome peak indicated that MPLA was
primarily associated with the virosomal membranes.
In vitro Analysis of RSV-MPLA Virosomes
To assess the immune-potentiating capacity of the RSV-MPLA
virosomes, fractions from the sucrose gradient were tested for their
TLR4-activating activity in HEK-Blue TLR4 cells, after dialysis to
remove the sucrose. The fractions containing the non-adjuvanted
virosomes induced a TLR4-mediated NF-kB activation which was
slightly higher than the activation induced by TNF-a (Figure 1C).
Thisactivation isprobablydue toTLRsignalingof theRSVFprotein
[35]. Incorporation of MPLA into the virosomes strongly stimulated
TLR4 signaling by the virosomes. The fraction at the top of the
gradient also induced activation of TLR4, indicating that not all the
added MPLA had been inserted in to the viral envelopes (Figure 1D).
Since a large proportion of the MPLA was associated with the
virosomal fraction, as judged by phosphate analysis and TLR4-
activating capacity of the fractions of the gradient, subsequent
experiments were performed with non-fractionated virosomes.
Next, virosomes were tested for their capacity to up-regulate
costimulatory molecules in mouse DCs. Non-adjuvanted viro-
somes induced the upregulation of DC maturation markers CD40,
CD80 and CD86. Incorporation of MPLA in to these virosomes
significantly stimulated the induction of CD40 and CD80
expression compared to the induction by RSV virosomes
(Figure 1 E).
Figure 2. RSV specific IgG in mice after vaccination with RSV virosomes and RSV-MPLA virosomes. Mice were vaccinated twice with RSV
virosomes, RSV-MPLA virosomes or controls (HNE, live virus and FI-RSV). Each injection contained 5 mg of protein. (A) RSV-specific IgG titers in serum
14 days after prime and 14 days after booster vaccination. (B) RSV-specific IgG1 and IgG2a subtype levels in serum 14 days after booster vaccination.
(C) IgE levels were determined at 14 days after booster vaccination. (D) RSV neutralizing antibody titers in serum obtained 5 days after challenge. Bars
represent the GMT (panels A and C), mean concentration of RSV-specific IgG1/2a (panel B) or mean neutralization titer (panel D) of 6 mice per group.
Error bars represent the SEM. Statistical differences were calculated using the Mann-Whitney-U test. *p,0.05, **p,0.01, ***p,0.001. Statistical
differences in IgE levels were calculated with an ANOVA with Bonferroni correction for multiple testing ***p,0.001. The data shown are
a representative of two individual experiments.
doi:10.1371/journal.pone.0036812.g002
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In vivo Immunogenicity
To analyze the immunogenicity of the virosomes in vivo, Balb/c
mice were vaccinated twice with RSV virosomes or RSV-MPLA
virosomes at a 2-week interval. For comparison, mice were
inoculated with live RSV (to induce a Th1-skewed immune
response) or vaccinated twice with FI-RSV (to induce a Th2-
skewed immune response). Two weeks after the first and second
vaccination, blood was drawn and serum IgG titers were
determined. After the priming immunization, RSV virosomes
induced a mean IgG titer of 2.5 Log GMT. Incorporation of
MPLA in to the virosomes resulted in significantly increased IgG
levels after both priming and booster immunizations, not only
compared to the levels induced by non-adjuvanted RSV virosomes
but also to the levels induced by FI-RSV and live virus (Figure 2A).
Next, RSV-specific IgG1 and IgG2a subtype levels were
determined. RSV-MPLA virosomes induced significantly higher
levels of IgG2a compared to non-adjuvanted virosomes, reaching
similar levels of RSV-specific IgG2a as seen after live virus
inoculation (Figure 2B). In parallel with the increased RSV-
specific IgG2a responses, increases in RSV-specific IgG1 levels
were also noted. Non-adjuvanted RSV virosomes and FI-RSV
mainly induced IgG1, indicative of a Th2-type response. Live virus
inoculations induced low levels of IgG1 and similar levels of
IgG2a, compared to those induced by RSV-MPLA virosomes
(Figure 2B).
To further characterize the humoral immune response, we
determined IgE levels in sera and IgA levels in BAL of immunized
mice. IgE was exclusively induced by immunization with FI-RSV,
but not by immunization with virosomes or live virus (Figure 2C).
IgA in BAL was detectable in mice immunized with FI-RSV
(4.660.1 2Log GMT) and live virus (5.660.6 2Log GMT), but not
in mice immunized with virosomes. For assessment of the
functional capacity of the antibodies, we performed a microneu-
tralization assay. Non-adjuvanted RSV virosomes induced similar
Figure 3. Influence of MPLA to virosome protein ratios on RSV specific IgG titers. Mice were vaccinated twice with RSV-MPLA virosomes
(5 mg of protein) with different amounts of incorporated MPLA. 14 days after the second vaccination RSV-specific IgG titers in serum were
determined. (A) RSV-specific IgG titers. (B) Ratio’s of RSV-specific IgG2a/IgG1 concentrations determined 14 days after booster vaccination. (C) RSV-
specific IgG1 concentrations. (D) RSV specific IgG2a concentrations. Bars represent the GMT (panel A), mean ratio (panel B) or mean concentration of
IgG1/2a of 6 mice per group. Error bars represent the SEM. Statistical differences were calculated using the Mann-Whitney-U test. *p,0.05, **p,0.01,
***p,0.001. The data shown are a representative of two individual experiments.
doi:10.1371/journal.pone.0036812.g003
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neutralizing antibody titers to FI-RSV. Incorporation of MPLA in
to the virosomes significantly increased the neutralizing antibody
titers to levels similar to those induced by live virus (Figure 2D).
To investigate which concentration of MPLA is needed for
optimal adjuvant activity, we added different amounts of MPLA to
the viral protein in solution before reconstitution. Apart from the
1:1 protein:MPLA ratio, we also produced virosomes with 1:0.2,
1:0.04 and 1:0.008 protein to MPLA ratios. Using a similar
immunization regimen and antigen dose as before, mice were
vaccinated, and RSV-specific serum IgG and subtype responses
were determined. The reduction in total RSV-specific serum IgG
induced by the vaccine was proportional to the decline in the
amount of MPLA in the virosomes (Figure 3A). The IgG2a/IgG1
subtype ratio remained similar when the amount of MPLA was
reduced from 1 to 0.2 mg/mg protein but decreased when the
amount of MPLA was reduced further (Figure 3B). This decrease
was primarily due to a reduction in RSV-specific IgG2a levels,
while the level of RSV-specific IgG1 did not increase significantly
with lower amounts of virosome-incorporated MPLA (Figure 3C,
3D). Because there was no significant difference between the IgG
subtypes induced by 1:1 and 1:0.2 protein to MPLA ratio
virosomes and there are other benefits to be expected from higher
MPLA concentrations (i.e. cellular immune response and re-
duction in lung pathology) we chose to perform the next
experiments with 1:1 protein:MPLA virosomes.
Cellular Immunity
To analyze if virosome-incorporated MPLA skews the immune
response to a favorable Th1 phenotype, levels of the hallmark Th1
cytokine IFNc and Th2 cytokine IL5 were determined in
splenocyte cultures of mice, ex vivo stimulated with RSV. Super-
natants of splenocytes cultures from mice immunized with RSV-
MPLA virosomes or infected with live virus produced significantly
increased levels of IFNc compared to those from mice immunized
with RSV virosomes alone or FI-RSV (Figure 4A) Restimulated
splenocytes from non-vaccinated mice produced considerable
levels of IFNc, which may be explained by activation of innate
immunity (i.e. NK cell activation) as a result of a high viral load
occurring in infected naı¨ve animals. Levels of IL5 were
significantly increased in splenocyte cultures from mice immunized
Figure 4. IFNc and IL5 concentrations in RSV-stimulated splenocyte cultures and lung tissue homogenates.Mice were vaccinated twice
with RSV virosomes, RSV-MPLA virosomes and control vaccines as in Figure 2, and subsequently challenged with live RSV. Four days after challenge,
IFNc and IL5 responses were determined. (A) IFNc concentrations in splenocyte cultures restimulated with BPL-inactivated RSV for three days. (B) IFNc
concentrations in homogenated lung tissue, four days after challenge. (C) IL5 concentrations in splenocyte cultures, restimulated with BPL-inactivated
RSV for three days. (D) IL5 concentrations in homogenated lung tissue, four days after challenge. Bars represent the mean cytokine concentration of 6
mice per group and error bars represent the SEM. Statistical differences were calculated using a Mann-Whitney-U test. *p,0.05, **p,0.01,
***p,0.001. The data shown are a representative of two individual experiments.
doi:10.1371/journal.pone.0036812.g004
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with FI-RSV when compared to those from all other groups
(Figure 4B).
Next, secretion of these cytokines was measured locally, i.e. in
lung homogenates, 4 days after viral challenge. In line with the
above data, mice immunized with RSV-MPLA virosomes showed
significantly increased IFNc levels in their lungs upon live virus
challenge when compared to levels measured in the lungs of mice
immunized with non-adjuvanted virosomes, FI-RSV or live virus
immunization (Figure 4C). Also, IL5 levels were significantly
increased in the lungs of FI-RSV immunized mice when
compared to the levels measured in the lungs of mice immunized
with (adjuvanted) RSV virosomes or live virus (Figure 4D).
Virus Clearance after Challenge
To analyze vaccination-induced virus clearance after challenge,
mice were immunized twice with HNE buffer, FI-RSV, live virus,
RSV virosomes or RSV-MPLA virosomes. Two weeks after the
second vaccination mice were challenged with 106 TCID50 live
RSV. Four days later, viral titers were determined in the lungs of
the animals. In the HNE vaccinated group, virus was recovered
from the lungs of all mice (Figure 5A). In three out of the six mice
immunized with RSV virosomes, virus could not be detected. In
the other mice, virus was detected albeit at a significant lower level
than in non-immunized mice. In contrast, in all mice immunized
with RSV-MPLA virosomes, FI-RSV and live virus, virus could
not be detected.
Lung Pathology
To further investigate ERD in the immunized mice, we
examined lung pathology upon challenge infection (Figure 6).
Mice immunized with FI-RSV showed signs of alveolitis and
infiltrates in both the peribronchial and perivascular areas
(Figure 6A). The lungs of mice immunized with live virus on the
other hand showed no signs of pathology (Figure 6B). Mice
immunized with RSV virosomes showed no signs of alveolitis but
did have perivascular infiltrates (Figure 6C) In contrast, the lungs
of the mice who received RSV-MPLA virosomes showed no signs
of lung pathology (Figure 6D) and were very similar to the lungs of
mice who received live virus or those of non-immunized mice
(Figure 6B,E). In addition to this, we assessed the presence of
eosinophils in broncho-alveolar lavages (BAL) four days after
challenge by May-Grunwald Giemsa staining of cytospotted cells.
No eosinophils were detected in BAL of mice vaccinated with
RSV or RSV-MPLA virosomes. On the other hand, in the mice
vaccinated with FI-RSV, eosinophils were clearly present
(Figure 6F).
Discussion
Despite the fact that RSV has been recognized as an important
vaccine target for more than 60 years, no vaccine is registered for
use in humans today. Various vaccine candidates have been
evaluated in clinical trials but so far none of them showed the
required safety and efficacy profiles. Generally, live attenuated
virus vaccines administered intranasally are safe and well tolerated
but it is difficult to obtain an optimal balance between
immunogenicity and attenuation [36]. Inactivated virus vaccines
appear to be hard to advance to the clinic because of the safety
concerns related to the outcome of the 1960’s FI-RSV trial.
Protein subunit vaccines are easy to produce but are generally not
very immunogenic and possibly skew towards a Th2 immune
response [36].
In this study, we evaluated the immunogenicity and protective
capacity of a virosomal RSV vaccine adjuvanted with MPLA.
Incorporation of the TLR4 ligand MPLA into the virosomal
membrane resulted in effective human TLR4 stimulation in HEK-
Blue cells in vitro and activation of mouse DC ex vivo as shown by
the upregulation of co-stimulatory molecules. Incorporation of
MPLA in virosomes resulted in increased RSV-specific serum IgG
titers, with production of RSV-specific, Th1-signature, IgG2a-
isotype antibodies similar to that induced by live virus inoculation
leading to a balanced IgG1/IgG2a profile. These antibodies
proved effective in virus neutralization. Furthermore, RSV-MPLA
virosomes skewed the cellular responses towards a Th1 profile, as
shown by enhanced IFN-c secretion, not only in ex vivo RSV-
stimulated splenocytes, but also locally in the lungs of infected
mice. Immunization with RSV-MPLA virosomes did not induce
any detectable IgE in contrast to immunization with FI-RSV. IgE
induction is a hallmark of a Th2-skewed allergy-like response,
which is implicated in RSV infections and in FI-RSV induced
enhanced disease [37–39]. MPLA-adjuvanted virosomes, similar
to FI-RSV, provided full protection against live RSV infection, but
in contrast to FI-RSV, did not lead to signs of ERD, i.e. influx of
eosinophils in the lungs or induction of lung pathology.
Importantly, previous studies in cotton rats showed that addition
of MPLA to FI-RSV reduces the induction of ERD by FI-RSV
immunization, illustrated by a reduction in lung pathology, an
increase in serum virus neutralization titers and a shift from a Th2
-skewed immune response to a balanced immune response
[31,32]. Our observations on the immune response induced by
MPLA-adjuvanted RSV virosomes in mice are in line with these
data and underline that MPLA-adjuvanted RSV virosomes hold
promise as a candidate RSV vaccine. Currently, RSV-MPLA
virosomes are being evaluated in cotton rats to optimally assess
other ERD parameters, such as alveolitis, in more detail.
Our data show that non-adjuvanted RSV virosomes stimulate
human TLR4 in HEK-Blue cells and upregulate co-stimulatory
molecules in mouse DC and that incorporated MPLA further
enhances these effects. TLR4 activation by RSV virosomes without
MPLA is likely to be caused by the RSV F protein. RSV F is a known
Figure 5. Protection against live virus challenge and infiltration
of eosinophils. Mice were vaccinated as described in figure 2 and
challenged with live virus 14 days after the booster vaccination. Four
days after challenge, lungs were removed and the viral titer was
determined and expressed as TCID50. RSV TCID50 titers from the lungs
of challenged animals. Statistical differences were calculated using the
Mann-Whitney-U test. *p,0.05. The data shown are a representative of
two individual experiments.
doi:10.1371/journal.pone.0036812.g005
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TLR4 agonist that, for example, induces inflammatory cytokines
like IL-6 in DC [35]. Interestingly, despite this capacity to stimulate
TLR4, RSV virosomes fail to induce Th1-type responses while
MPLA, also a TLR4 agonist, effectively stimulates Th1-type
responses. This could be due to differences in the magnitude of
stimulation, which is clearly higher for MPLA (Figure 1), but could
also be caused by recruitment of different adaptor molecules
downstream of TLR4 activation. As TLR4 uses both MyD88 and
TRIF adaptor molecules, it is possible that MPLA competes with
RSV F for TLR4 activation. This competition shifts signaling from
RSV F-induced, MyD88-dependent, TLR4 signaling to MPLA-
induced, TRIF-dependent, TLR4 signaling, leading to a Th1-
skewed immune response induced by RSV-MPLA virosomes
compared to non-adjuvanted RSV virosomes.
Apart from its influence on T helper cell differentiation, TLR
signaling also has a direct effect on IgG isotype switching [40].
Antibody isotype switching is important, because different
immunoglobulin subclasses display differences in their ability
to mediate effector responses [41]. In mice, the most effective
IgG isotype protecting against viral infections is IgG2a [42]. As
stated before, MPLA signals through TLR4 to induce type I
IFNs which stimulate IgG2a production predominantly from
follicular B cells [40]. Furthermore, MPLA could also directly
activate TLR4 on B cells to facilitate isotype switching, a process
that is further augmented by IFNc and T-cell help [43].
Previously, we incorporated TLR2 ligand P3CSK4 in RSV
virosomes. P3CSK4 inclusion also skewed towards a Th1
immune response and increased IgG2a levels compared to
Figure 6. Lung pathology in mice after immunization and RSV infection.Mice were immunized and challenged as described in Figure 2 and
the lungs were harvested, sliced and stained with H&E and assessed for pathology using light microscopy. Panels represent the lungs of (A) FI-RSV, (B)
live virus, (C) RSV virosomes, (D) RSV MPLA virosomes (E) buffer immunized mice. Black arrows point to alveolar infiltrates, grey arrows to
peribronchial infiltrates and white arrows to perivascular infiltrates. (F) Eosinophils in BAL expressed as percentage of total BAL cells. Data points
represent values from individual mice. Statistical differences were calculated using the ANOVA test with Bonferroni correction for multiple testing.
***p,0.001. The data shown are a representative of two individual experiments.
doi:10.1371/journal.pone.0036812.g006
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non-adjuvanted virosomes. P3CSK4 adjuvanted RSV virosomes
did however, induce slightly higher IgG1 than IgG2a levels.
Incorporation of MPLA in the virosomes induces similar IgG1
and IgG2a levels. The relative increase of IgG2a levels
compared to P3CSK4-RSV virosomes could be due to in-
creased type I IFN production induced by MPLA. Since
incorporation of MPLA in virosomes increases IgG2a levels
compared to non-adjuvanted RSV virosomes or FI-RSV,
antibodies induced by RSV-MPLA virosomes may well be
more effective in protection against viral infection than
antibodies induced by the non-adjuvanted RSV virosomes or
FI-RSV.
Production of virosomes does not include the application of
cross-linking chemicals for inactivation of the virus. This could
well be a major advantage of the use of virosomes compared to
other approaches using whole inactivated virus. In this respect, it is
important to note that one of the reasons why FI-RSV failed to
elicit virus-neutralizing antibodies is that important epitopes on the
virus are disrupted by formalin [44]. One of the most important
RSV epitopes for neutralizing antibodies is a specific conforma-
tional epitope making it very susceptible for alteration by chemical
treatments, including inactivation with formalin [45]. During
virosome production, inactivation occurs through disruption of the
membrane by the short-chain phospholipid DCPC followed by
removal of the nucleocapsid. This is then followed by re-
constitution of RSV F and G protein in the viral membrane with
retention of their native conformation. Following this procedure,
RSV virosomes lack viral RNA and thus are fully replication-
incompetent [21]. Preliminary data indicate that RSV virosomes
expose all of the most important known protective on the RSV F
protein, as demonstrated by efficient binding of monoclonal
antibodies directed to these epitopes (unpublished results).
In conclusion, our data show the feasibility of producing RSV
virosomes that have incorporated MPLA. MPLA improves the
immunogenicity of RSV virosomes and skews immune response to
a protective, balanced Th1/Th2-type response without priming
for adverse immune reactions, such as eosinophil influx into the
lung after infection with RSV. These data combined with the
favorable safety profile of MPLA, and the fact that MPLA is
already licensed for use in human vaccines, make the RSV-MPLA
virosomal vaccine a suitable candidate for further evaluation in
clinical trials.
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